STOCK TITAN

[Form 4] Quanterix Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Mendel Scott, a director of Quanterix Corp (QTRX), received 2,084 shares of common stock on 10/01/2025 as stock issued in lieu of cash board fees for Q3 2025 at a closing price of $5.54. Following the issuance, Mr. Scott beneficially owns 30,737 shares, which include 24,464 restricted stock units. The Form 4 was signed on behalf of the reporting person by Brian Keane, Attorney-in-Fact. The filing discloses no derivative transactions, option grants, or other cash purchases in this report.

Mendel Scott, un direttore di Quanterix Corp (QTRX), ha ricevuto 2,084 azioni ordinarie il 10/01/2025 come azioni emesse in luogo di contanti per i compensi di consiglio relativi al Q3 2025, al prezzo di chiusura di $5.54. Dopo l’emissione, il signor Scott detiene beneficiamente 30,737 azioni, tra cui 24,464 restricted stock units. Il Form 4 è stato firmato per conto della persona che segnala da Brian Keane, Attorney-in-Fact. La dichiarazione non riporta derivati, assegnazioni di opzioni o altri acquisti in contanti in questo rapporto.

Mendel Scott, un director de Quanterix Corp (QTRX), recibió 2,084 acciones comunes el 10/01/2025 como acciones emitidas en lugar de efectivo por honorarios de la junta para el Q3 2025 a un cierre de $5.54. Tras la emisión, el Sr. Scott posee beneficiosamente 30,737 acciones, que incluyen 24,464 restricted stock units. El Form 4 fue firmado en nombre de la persona reportante por Brian Keane, Attorney-in-Fact. La presentación no revela transacciones derivadas, otorgamientos de opciones u otras compras en efectivo en este informe.

Mendel Scott , Quanterix Corp (QTRX)Director인 그는 2025년 10/01/2025에 현금 대신 주식으로 지급된 보드 수수료로 2,084주의 보통주를 받았으며 종가가 $5.54였다. 발행 후, 스콧 씨는 30,737주를 실질적으로 소유하게 되며 그 중 24,464 restricted stock units가 포함되어 있다. Form 4는 보고자 대리인인 Brian Keane, Attorney-in-Fact가 서명했다. 이 보고서는 파생 거래, 옵션 부여 또는 현금 구매에 관한 거래를 공시하지 않는다.

Mendel Scott, directeur de Quanterix Corp (QTRX), a reçu 2 084 actions ordinaires le 01/10/2025 en actions émises en lieu de liquidités pour des frais de conseil du conseil au titre du Q3 2025, à un cours de clôture de $5,54. Après l’émission, M. Scott détient bénéficiairement 30 737 actions, dont 24 464 unités d’actions restrictives. Le Formulaire 4 a été signé au nom de la personne déclarant par Brian Keane, Attorney-in-Fact. Le dépôt ne révèle aucune transaction dérivée, attribution d’options ou autres achats en espèces dans ce rapport.

Mendel Scott, ein Direktor von Quanterix Corp (QTRX), erhielt am 01.10.2025 2.084 Stammaktien als Aktienausgabe statt Bargeld für Vorstandsgebühren im Q3 2025 bei einem Schlusskurs von $5,54. Nach der Emission besitzt Herr Scott beneficiell 30.737 Aktien, darunter 24.464 Restricted Stock Units. Das Formular 4 wurde im Namen der meldenden Person von Brian Keane, Attorney-in-Fact unterzeichnet. Die Einreichung weist keine Derivategeschäfte, Optionszuteilungen oder sonstige Barkäufe in diesem Bericht aus.

مندل سكوت، مدير في Quanterix Corp (QTRX)، تلقّى 2,084 سهماً عادياً في 10/01/2025 كإصدار أسهم عوضاً عن النقد مقابل أ-/ رسوم مجلس الإدارة للربع الثالث من 2025 بسعر إغلاق قدره $5.54. بعد الإصدار، يمتلك السيد سكوت بشكل فعّال 30,737 سهماً، من بينها 24,464 وحدة أسهم مقيدة. تم توقيع النموذج 4 نيابة عن الشخص المبلّغ من قبل Brian Keane, Attorney-in-Fact. لا تُشير الإيداع إلى أي معاملات مشتقة أو منح خيارات أو أي شراءات نقدية أخرى في هذا التقرير.

Mendel Scott,是 Quanterix Corp (QTRX)董事,于 2025/10/01 收到 2,084 股普通股,作为第三季度董事会费用的以股代替现金发放,收盘价为 $5.54。发行后,Scott 先生实际持有 30,737 股,其中包括 24,464 股受限股票单位(RSU)。Form 4 由报告人代理人 Brian Keane, Attorney-in-Fact 签署。该备案未披露任何衍生交易、期权授予或本报告中的其他现金购买。

Positive
  • None.
Negative
  • None.

Mendel Scott, un direttore di Quanterix Corp (QTRX), ha ricevuto 2,084 azioni ordinarie il 10/01/2025 come azioni emesse in luogo di contanti per i compensi di consiglio relativi al Q3 2025, al prezzo di chiusura di $5.54. Dopo l’emissione, il signor Scott detiene beneficiamente 30,737 azioni, tra cui 24,464 restricted stock units. Il Form 4 è stato firmato per conto della persona che segnala da Brian Keane, Attorney-in-Fact. La dichiarazione non riporta derivati, assegnazioni di opzioni o altri acquisti in contanti in questo rapporto.

Mendel Scott, un director de Quanterix Corp (QTRX), recibió 2,084 acciones comunes el 10/01/2025 como acciones emitidas en lugar de efectivo por honorarios de la junta para el Q3 2025 a un cierre de $5.54. Tras la emisión, el Sr. Scott posee beneficiosamente 30,737 acciones, que incluyen 24,464 restricted stock units. El Form 4 fue firmado en nombre de la persona reportante por Brian Keane, Attorney-in-Fact. La presentación no revela transacciones derivadas, otorgamientos de opciones u otras compras en efectivo en este informe.

Mendel Scott , Quanterix Corp (QTRX)Director인 그는 2025년 10/01/2025에 현금 대신 주식으로 지급된 보드 수수료로 2,084주의 보통주를 받았으며 종가가 $5.54였다. 발행 후, 스콧 씨는 30,737주를 실질적으로 소유하게 되며 그 중 24,464 restricted stock units가 포함되어 있다. Form 4는 보고자 대리인인 Brian Keane, Attorney-in-Fact가 서명했다. 이 보고서는 파생 거래, 옵션 부여 또는 현금 구매에 관한 거래를 공시하지 않는다.

Mendel Scott, directeur de Quanterix Corp (QTRX), a reçu 2 084 actions ordinaires le 01/10/2025 en actions émises en lieu de liquidités pour des frais de conseil du conseil au titre du Q3 2025, à un cours de clôture de $5,54. Après l’émission, M. Scott détient bénéficiairement 30 737 actions, dont 24 464 unités d’actions restrictives. Le Formulaire 4 a été signé au nom de la personne déclarant par Brian Keane, Attorney-in-Fact. Le dépôt ne révèle aucune transaction dérivée, attribution d’options ou autres achats en espèces dans ce rapport.

Mendel Scott, ein Direktor von Quanterix Corp (QTRX), erhielt am 01.10.2025 2.084 Stammaktien als Aktienausgabe statt Bargeld für Vorstandsgebühren im Q3 2025 bei einem Schlusskurs von $5,54. Nach der Emission besitzt Herr Scott beneficiell 30.737 Aktien, darunter 24.464 Restricted Stock Units. Das Formular 4 wurde im Namen der meldenden Person von Brian Keane, Attorney-in-Fact unterzeichnet. Die Einreichung weist keine Derivategeschäfte, Optionszuteilungen oder sonstige Barkäufe in diesem Bericht aus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mendel Scott

(Last) (First) (Middle)
C/O QUANTERIX CORPORATION
900 MIDDLESEX TURNPIKE

(Street)
BILLERICA MA 01821

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Quanterix Corp [ QTRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 A 2,084(1) A $5.54(2) 30,737(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2025.
2. Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2025.
3. Includes 24,464 restricted stock units.
Remarks:
/s/ Brian Keane, as Attorney-in-Fact 10/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Quanterix

NASDAQ:QTRX

QTRX Rankings

QTRX Latest News

QTRX Latest SEC Filings

QTRX Stock Data

273.22M
43.46M
6.46%
73.43%
9.05%
Medical Devices
Laboratory Analytical Instruments
Link
United States
BILLERICA